


Supplementary Figure 1: Flowchart of patients.



Supplementary Table 1: Demographics and clinical characteristics of participants.

Parameters	PsA (n=40)	PsC (n=475)	P values
Gender (male), n (%)	29 (72.5)	331 (69.7)	0.709
Age (years), mean (SD)	42.23 (12.09)	37.26 (10.38)	0.004
BMI (kg/m ²), mean (SD)	24.90 (3.48)	24.26 (4.22)	0.350
Normal, n (%)	17 (42.5)	240 (50.5)	
Overweight, n (%)	18 (45)	162 (34.1)	0.381
Obesity, n (%)	5 (12.5)	73 (15.4)	
Smoking (ever), n (%)	11 (27.5)	158 (33.3)	0.456
Comorbidity, n (%)			
HTN	6 (15.0)	45 (9.5)	0.396
Diabetes	3 (7.5)	13 (2.7)	0.233
CHD	2 (5.0)	10 (2.1)	0.237
Hyperlipidemia	2 (5.0)	37 (7.8)	0.742
Gout	2 (5.0)	23 (4.8)	1.000
Stroke	0	1 (0.2)	/
Duration of psoriasis (years), mean (SD)	20.30 (12.35)	16.27 (10.47)	0.021
Family history of psoriasis, n (%)	18 (45.0)	165 (34.7)	0.193
BSA, mean (SD)	15.00 (24.58)	10.20 (20.70)	0.166
Mild (<3), n (%)	16 (40.0)	245 (51.6)	
Moderate (3–10), n (%)	13 (32.5)	158 (33.3)	0.107
Severe (>10), n (%)	11 (27.5)	72 (15.2)	
Treatment			
Topical therapy, n (%)	24 (60.0)	305 (64.2)	0.594
Oral glucose, n (%)	0	18 (3.8)	0.421
Phototherapy, n (%)	5 (12.5)	66 (13.9)	0.806
DMARDs, n (%)	3 (7.5)	21 (4.4)	0.619
Biologics, n (%)	7 (17.5)	98 (20.6)	0.637
Others, n (%)	15 (37.5)	147 (30.9)	0.391

PsC: Cutaneous-only psoriasis; SD: Standard deviation; BMI: Body mass index; HTN: Hypertension; CHD: Coronary heart disease; BSA: Body surface area; DMARDs: Disease-modifying antirheumatic drugs.